β-受体阻滞剂在临床高血压治疗中的独立作用及降压效果对照研究
周琰
（西安工程大学校医院，陕西 西安，710048）
浏览次数：70次 下载次数：407次
摘要：
目的 分析β-受体阻滞剂在高血压治疗中的应用价值。方法 选择2015年2月至2016年8月门诊随访的高血压患者 274例，血压控制者纳入控制组，未获得控制者纳入未控制组，对两组患者进行单因素分析；选择2015年1月至2016年2月高血压患者84例，分为对照组和试验组，各42例，均采用硝苯地平缓释片治疗，试验组联合β原受体阻滞剂治疗，比较两组治疗前、后血压及HR水平。结果 274例患者的血压控制率为37.59%，控制组和未控制组使用β -受体阻滞剂比较，差异无统计学意义（P> 0.05）；治疗后，试验组与对照组SBP、DBP、HR 低于治疗前，且试验组低于对照组（P<0.05）。结论 β-受体阻滞剂可辅助治疗高血压，但独立应用较其他药物无优势。
关键词：高血压；β-受体阻滞剂；个体化用药
中图分类号：R544.1 文献标志码：A文章编号：2096-1413(2017)18-0039-02
Clinical controlled study of independent effect of beta blockers in the treatment of hypertension and antihypertensive
ZHOU Yan
(Xi``an Polytechnic University Hospital, Xi``an 710048, China)
ABSTRACT: Objective To analyze the application value of beta blockers in the treatment of hypertension. Methods From February 2015 to August 2016, 274 patients with hypertension outpatient follow-up cases were selected, the blood pressure controllers were included in the control group, and the other without control were included in the uncontrolled group, the univariate analysis of the two groups were taken. From January 2015 to February 2016, 84 cases of patients with hypertension were divided into blank group and experimental group, with 42 cases in each group. Both groups were treated with nifedipine sustained -release tablets, while the experimental group added beta blockers, and the levels of blood pressure and HR were compared between the two groups before and after treatment. Results The blood pressure control rate of the 274 cases was 37.59%, and there was no significant difference in the proportion of beta blockers between the control group and the uncontrolled group (P>0.05). After treatment, the SBP, DBP and HR of the experimental group and the control group were lower than those before treatment, and the experimental group was lower than the control group (P<0.05). Conclusion Beta blockers can be adjuvant to treat hypertension, but independent use has no advantage over other drugs.
KEYWORDS: hypertension; beta blockers; individualized treatment
参考文献：
[1] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心血管病预防指南[J].中华心血管病杂志,2011,39(1):3-22.
[2] 王文.茁原受体阻滞剂在高血压治疗中的地位和再评价[J].中华高血压杂志,2013,21(8):715-718.
[3] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J]. 中华高血压杂志,2011,19(8):701-703.
[4] 中华医学会老年医学分会,中国医师协会高血压专业委员会.老年高血压特点与临床诊治流程专家建议[J].中华高血压杂志,2014,22(7):620-627.
[5] 李勇.美托洛尔在老年高血压治疗中的疗效Meta 分析[J].遵义:遵义医学院,2016.
[6] NANCHEN D,LEENING MJ,LOCATELLI I,et al.Resting heart rate and the risk of heart failure in healthy adults: the Rotterdam Study[J]. Circ Heart Fail,2013,6(3):403-410.
[7] 苏镇培.老年高血压的诊治、评2011 中国美国欧洲老年高血压专家共识[J].中华高血压杂志,2014,22(3):214-217.
[8] 闫森,孙党辉,李悦.茁 受体阻滞剂治疗高血压存在的问题和展望[J].中华高血压杂志,2014,22(2):101-103.
[9] 赵天涯,高苹,林梅.第三代茁 受体阻滞剂在糖尿病合并高血压患者中应用的研究进展[J].中华高血压杂志,2014,22(4):332-335.
[10] 高平进,李华.难治性高血压诊治对策[J].中国实用内科杂志,2012,32(1):8-11.